{
    "nct_id": "NCT00110552",
    "title": "Effects of a Cognitive Enhancer on Memory and Cognitive Performance",
    "status": "COMPLETED",
    "last_update_time": "2014-10-27",
    "description_brief": "The purpose of this study is to determine the effectiveness of the herb sage in improving the mental function of individuals with Alzheimer's disease.\n\nStudy hypothesis: The administration of sage will improve cognitive function in patients with mild Alzheimer's disease.",
    "description_detailed": "The herb sage has been shown to enhance memory and mental function in healthy, young adults. However, studies assessing the herb's effectiveness in older adults with symptoms of Alzheimer's disease are limited. This study will determine the effect of sage extract on the cognitive function of patients with mild Alzheimer's disease.\n\nThis study will last 6 weeks and will comprise 4 study visits, approximately 10 days apart. Participants will be randomly assigned to receive either sage pills or no treatment during each 10-day period. The treatment assignments will be switched in 10-day intervals, so that during the course of the study, each participant will undergo two periods of sage treatment and two periods without treatment. At each study visit, participants will undergo cognitive testing, including tests to determine attention, memory, and visual cognition. Participants will also undergo an electroencephalogram (EEG) and an electrocardiogram (ECG) at each visit.",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "cognitive enhancer",
    "drug": [
        "Sage (Salvia officinalis / Salvia lavandulaefolia \u2014 herbal extract or essential oil)"
    ],
    "placebo": [
        "Not specified in the provided description (many trials use placebo controls)"
    ],
    "explanation_target": [
        "Reason: The intervention is the herb \"sage\" given to people with mild Alzheimer\u2019s disease to improve \"mental function\" / \"cognitive function\" \u2014 the stated aim is symptomatic improvement of memory and cognition rather than explicit disease modification. This fits the 'Cognitive enhancer' category (drugs/interventions intended to improve cognitive performance rather than directly target underlying AD pathology).",
        "Act: Key details extracted from the description \u2014 intervention = sage (herbal), intended effect = improve cognitive function/memory in mild AD. Sage extracts (Salvia officinalis and Salvia lavandulaefolia) have been tested in clinical trials and have shown cognitive-enhancing effects in healthy volunteers and in at least one randomized trial in patients with mild\u2013moderate Alzheimer\u2019s disease. \ue200cite\ue202turn0search2\ue202turn0search4\ue201",
        "Supporting mechanism and evidence: Sage extracts/essential oils show acetylcholinesterase (AChE) inhibitory activity and other relevant actions (antioxidant, anti-inflammatory); these pharmacologic effects help explain cognition improvement in trials. \ue200cite\ue202turn0search3\ue202turn0search7\ue201",
        "Additional supporting studies/review: In-vitro and animal data indicate constituents such as rosmarinic acid can reduce amyloid-beta\u2013induced toxicity (mechanistic evidence but not definitive disease-modifying proof). A systematic review concluded Salvia species exert beneficial effects on memory and cognitive impairment but highlighted methodological heterogeneity and need for larger trials. \ue200cite\ue202turn0search1\ue202turn0search8\ue201",
        "Reflect: Given the trial description and the published literature showing sage improves cognitive performance acutely and in at least one AD trial, the correct classification is 'cognitive enhancer'. Ambiguities: the provided description does not specify the Salvia species, formulation (essential oil vs. extract), dose, or whether the trial uses placebo control \u2014 these details would not change the category but are relevant to interpreting results."
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The trial tests sage (Salvia officinalis / S. lavandulaefolia) as a symptomatic cognitive enhancer in people with mild Alzheimer\u2019s disease. The dominant, well-documented pharmacologic action of sage extracts/essential oils relevant to improved cognition is inhibition of acetylcholinesterase (increases acetylcholine signaling), i.e., modulation of cholinergic neurotransmission. This mechanism places the intervention within neurotransmitter/cholinergic modulation rather than a disease\u2011modifying category. \ue200cite\ue202turn0search5\ue202turn0search6\ue201",
        "Act: Key details extracted \u2014 intervention = sage (Salvia officinalis / S. lavandulaefolia; extract or essential oil), intended effect = symptomatic improvement in memory/cognition in mild AD. A placebo\u2011controlled randomized trial of Salvia officinalis reported cognitive benefit in mild\u2013moderate AD, and other human studies (including healthy volunteer trials) report acute and longer\u2011term cognitive enhancement with sage preparations. These clinical findings and the cholinesterase inhibition data support assigning the CADRO category focused on neurotransmitter modulation. \ue200cite\ue202turn0search0\ue202turn0search1\ue202turn0search2\ue201",
        "Reflect: Classification check \u2014 the principal, load\u2011bearing mechanism is enhancement of cholinergic neurotransmission via acetylcholinesterase inhibition (and possibly receptor/neuromodulatory effects), so D) Neurotransmitter Receptors is the most specific CADRO match. Although sage also has antioxidant and anti\u2011inflammatory activities and some preclinical data suggest effects on amyloid\u2011related toxicity, those are secondary/mechanistic signals rather than the primary symptomatic target in the described trial; therefore 'Multi\u2011target' or a disease\u2011modifying CADRO category is not appropriate based on the provided description. \ue200cite\ue202turn0search5\ue202turn0search4\ue201",
        "Web search results supporting the classification (selected): 1) Randomized, placebo\u2011controlled trial of Salvia officinalis extract in mild\u2013moderate AD (Akhondzadeh et al.). \ue200cite\ue202turn0search0\ue201 2) Trials showing Salvia lavandulaefolia (Spanish sage) enhances memory in healthy volunteers; studies report acetylcholinesterase association. \ue200cite\ue202turn0search1\ue202turn0search6\ue201 3) Reviews and pharmacology papers summarizing sage\u2019s AChE\u2011inhibitory, antioxidant and anti\u2011inflammatory properties and clinical pilot data in dementia. \ue200cite\ue202turn0search5\ue202turn0search4\ue201",
        "Output: D) Neurotransmitter Receptors \u2014 Sage is best classified under neurotransmitter/cholinergic modulation (symptomatic cognitive enhancer) given its acetylcholinesterase\u2011inhibitory and cognition\u2011enhancing actions, supported by clinical trial evidence and pharmacologic studies."
    ]
}